Drug development of clavulanic acid, a GLT-1 activator: proof of concept for cocaine use disorder
GLT-1 激活剂克拉维酸的药物开发:可卡因使用障碍的概念证明
基本信息
- 批准号:10597589
- 负责人:
- 金额:$ 138.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-15 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAddressAdultAmoxicillin-Potassium Clavulanate CombinationAnimalsAnteriorAntibioticsAreaBackBehaviorBehavior TherapyBiological MarkersBrainBrain regionCause of DeathCensusesCessation of lifeChronicClavulanic AcidsClinicalCocaineCocaine AbuseCocaine DependenceCocaine use disorderCorpus striatum structureCuesDataDeath RateDedicationsDevelopmentDevelopment PlansDisease remissionDoseEffectivenessExtracellular SpaceFormulationFunctional Magnetic Resonance ImagingGlutamate TransporterGlutamatesGoalsHalf-LifeHumanInpatientsIntellectual PropertyIntravenousInvestigationMagnetic Resonance SpectroscopyMeasuresMediatingMethamphetamineModelingMotivationMusNeurotransmittersNucleus AccumbensOralOutpatientsOverdosePatient Self-ReportPatientsPersonsPharmaceutical PreparationsPharmacologic SubstancePhasePlacebo ControlPlacebosPublishingRandomizedRattusReportingResearchRestRodentSafetyScheduleSerumSiteTestingTherapeutic EffectTitrationsToxic effectUrineaddictionalcohol preferring ratsbenzoylecgoninebeta-Lactamscingulate cortexclinical developmentcocaine cravingcocaine cuecocaine exposurecocaine seekingcocaine self-administrationcocaine useconditioned place preferencecravingdrug developmentefficacy studyextracellularimprovedmeetingsnovel therapeuticsoverdose deathpreclinical developmentpreclinical studypsychostimulantresponsesafety studytherapeutic effectivenesstimelinevolunteer
项目摘要
Cocaine-related overdose deaths are rapidly rising in the U.S. An effective medication for cocaine addiction is
urgently needed. This proposal aims to determine whether clavulanic acid (CLAV) is effective in treating
cocaine use disorder. Animal studies suggest that activation of GLT-1, the dominant astroglial glutamate
transporter responsible for clearing extracellular glutamate, may provide a breakthrough approach to managing
cocaine addiction. Studies in rodents demonstrate that CLAV, a non-antibiotic component of the commonly
used antibiotic Augmentin, has short-term effects to a) increase GLT-1 activity, thus reducing extracellular
glutamate in brain areas associated with addiction, i.e., the nucleus accumbens (NAc) and its afferent limbic
region, the anterior cingulate cortex (AC), and b) inhibit the reinforcing strength of cocaine in a model of
cocaine self-administration. We have concluded an inpatient study, required by the FDA, showing that the co-
administration of CLAV and cocaine to volunteer non-treatment-seeking adults with cocaine use disorder is
associated with decreased cocaine craving and produces no serious toxicity. Using magnetic resonance
spectroscopy (MRS) at 3T, we have human pilot data demonstrating changes in brain glutamate in the AC
after the first dose of CLAV, and this is maintained for 10 days of daily CLAV dosing. We now propose two
human trials to assess the therapeutic effectiveness of CLAV: 1) We will determine whether CLAV maintains
its therapeutic effects to reduce cocaine craving when given orally once-a-day, since CLAV has a very short
half-life in the serum. Glutamate levels in the AC, measured after cessation of CLAV dosing, will be used as a
biomarker to assess whether CLAV can be dosed once daily. Resting state functional connectivity will
determine whether the AC increases target engagement with the NAc, and whether network deficits associated
with chronic cocaine use are improved by repeated CLAV. 2) In subjects who tolerate CLAV 500 mg/day, we
will determine the effects, safety and tolerability of CLAV 750 mg/day. 3) Finally, we will conduct a
randomized, placebo controlled multi-site, outpatient efficacy study of CLAV in cocaine-addicted patients
seeking treatment, using a formulation for once-daily dosing as determined in 2). If efficacy is confirmed (Go-
No Go decision point), the project will transition to our pharmaceutical company partner, VistaGen, who will be
supporting formulation development, intellectual property and regulatory strategy, as well as clinical and
preclinical development during this proposal. With VistaGen, we will schedule an FDA meeting to explore
breakthrough therapy status and discuss development plans leading to a New Drug Application submission.
在美国,与可卡因有关的过量死亡人数正在迅速上升。治疗可卡因成瘾的有效药物是
急需之物。这项建议旨在确定克拉维酸(CLAV)是否有效
可卡因使用障碍。动物研究表明,主要的星形胶质谷氨酸GLT-1的激活
负责清除胞外谷氨酸的转运体,可能提供一种突破性的管理方法
可卡因成瘾。在啮齿动物身上的研究表明,爪状病毒,一种常见的
使用抗生素Augentin,有短期效果:a)增加GLT-1活性,从而减少细胞外
与成瘾有关的脑区,即伏隔核(NAC)及其传入边缘的谷氨酸
前扣带回皮质(AC)和b)抑制可卡因的增强强度。
可卡因自我管理。根据FDA的要求,我们已经完成了一项住院研究,结果显示,
对患有可卡因使用障碍的未寻求治疗的成年人自愿给予CLAV和可卡因的管理是
减少对可卡因的渴求,不会产生严重的毒性。使用磁共振
波谱(MRS)在3T,我们有人类飞行员的数据显示AC中大脑谷氨酸的变化
在第一剂CLAV之后,这将维持10天的每日CLAV剂量。我们现在提出两个建议
评估CLAV治疗效果的人体试验:1)我们将确定CLAV是否维持
它的治疗作用是减少对可卡因的渴求,每天口服一次,因为CLAV的有效期很短
血清中的半衰期。停止给药后,AC中的谷氨酸水平将被用作
生物标志物,以评估CLAV是否可以每天给药一次。休眠状态功能连接将
确定AC是否增加了与NAC的目标接洽,以及网络缺陷是否相关
对于长期使用可卡因的患者,通过反复使用CLAV可以改善病情。2)在每天耐受CLAV500毫克的受试者中,我们
将决定CLAV750毫克/天的疗效、安全性和耐受性。3)最后,我们将进行一次
CLAV治疗可卡因成瘾患者的随机、安慰剂对照、多点门诊疗效研究
寻求治疗,使用2)中确定的每日一次剂量的配方。如果疗效得到确认(Go-
没有进入决策点),该项目将过渡到我们的制药公司合作伙伴VistaGen,他将
支持配方开发、知识产权和监管战略,以及临床和
在这项提议期间的临床前发展。有了VistaGen,我们将安排一次FDA会议来探索
突破性的治疗现状,并讨论导致新药申请提交的发展计划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mary F. Morrison其他文献
How to study the impact of sex and gender in medical research: a review of resources
- DOI:
10.1186/s13293-016-0099-1 - 发表时间:
2016-10-01 - 期刊:
- 影响因子:5.100
- 作者:
Alyson J. McGregor;Memoona Hasnain;Kathryn Sandberg;Mary F. Morrison;Michelle Berlin;Justina Trott - 通讯作者:
Justina Trott
6.60 DEMOGRAPHICS OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND TREATMENT MODALITIES: AN ANALYSIS OF NATIONAL AMBULATORY MEDICAL CARE SURVEY DATA FROM 2009 - 2012
- DOI:
10.1016/j.jaac.2016.09.379 - 发表时间:
2016-10-01 - 期刊:
- 影响因子:
- 作者:
Jaclyn Dietzold;Anisha Garg;Ian Peters;Christopher Combs;Rachel M. Peters;Mary F. Morrison - 通讯作者:
Mary F. Morrison
Depression in the medical setting: biopsychological interactions and treatment considerations.
医疗环境中的抑郁症:生物心理学相互作用和治疗注意事项。
- DOI:
- 发表时间:
1999 - 期刊:
- 影响因子:5.3
- 作者:
Dwight L. Evans;Jeffrey P. Staab;J. Petitto;Mary F. Morrison;M. Szuba;Herbert E. Ward;B. J. Wingate;M. P. Luber;J. O'reardon - 通讯作者:
J. O'reardon
Specialized community disease management to reduce substance use and hospital readmissions
- DOI:
10.1016/j.drugalcdep.2016.08.115 - 发表时间:
2017-02-01 - 期刊:
- 影响因子:
- 作者:
Jaclyn E. Chambers;Adam C. Brooks;Mary F. Morrison;James R. McKay;David R. Gastfriend - 通讯作者:
David R. Gastfriend
Mary F. Morrison的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 138.83万 - 项目类别:
Research Grant